Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

berlin-chemie ag (menarini group) - dapoxetinum - comprimate filmate - 60 mg

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

emcure pharmaceuticals ltd - dapoxetinum - comprimate filmate - 30 mg

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

desitin arzneimittel gmbh - carbamazepinum - suspensie orala - 100 mg/5ml

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

desitin arzneimittel gmbh - carbamazepinum - comprimate cu eliberare prelungită - 150 mg

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

desitin arzneimittel gmbh - carbamazepinum - comprimate cu eliberare prelungită - 300 mg

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

desitin arzneimittel gmbh - carbamazepinum - comprimate cu eliberare prelungită - 600 mg

Uniunea Europeană - română - EMA (European Medicines Agency)

janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.

Uniunea Europeană - română - EMA (European Medicines Agency)

takeda pharma a/s - citrat de fentanil - pain; cancer - analgezice - instanyl este indicat pentru gestionarea durerii descoperite la adulții care primesc deja tratament de întreținere cu opioide pentru durerea cronică a cancerului. durerea descendentă este o exacerbare tranzitorie a durerii care apare pe fundalul unei dureri persistente controlate în alt mod.  patients receiving maintenance opioid therapy are those who are taking at least 60 mg of oral morphine daily, at least 25 micrograms of transdermal fentanyl per hour, at least 30 mg oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer.

Uniunea Europeană - română - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - guanfacină clorhidrat - tulburare de deficit de atenție cu hiperactivitate - antiadrenergic agents, centrally acting, antihypertensives, - intuniv is indicated for the treatment of attention deficit hyperactivity disorder (adhd) in children and adolescents 6 17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective. intuniv trebuie să fie folosit ca o parte dintr-un amplu tratament adhd program, de obicei, inclusiv psihologice, educaționale și sociale măsuri.

Uniunea Europeană - română - EMA (European Medicines Agency)

incline therapeutics europe ltd - fentanil clorhidrat - durere, postoperator - analgezice - ionsys este indicat pentru tratamentul durerii postoperatorii moderate până la severe la pacienții adulți.